Request for Nominations to the Advisory Council on Alzheimer's Research, Care, and Services, 23797-23798 [2019-10775]
Download as PDF
<![CDATA[
23797
Federal Register / Vol. 84, No. 100 / Thursday, May 23, 2019 / Notices
Abstract: This Information Collection
Request is for continued approval of
performance measures for HRSA’s
Maternal and Child Health Bureau
(MCHB) discretionary grants,
specifically, the continued use of
reporting requirements for grant
programs administered by MCHB in
accordance with the ‘‘Government
Performance and Results Act of 1993’’
(Pub. L. 103–62). This Act requires the
preparation of an annual performance
plan covering each program activity set
forth in the agency’s budget, which
includes establishment of measurable
goals that may be reported in an annual
financial statement to support the
linkage of funding decisions with
performance. Performance measures for
MCHB discretionary grants were
initially approved in 2003, and the
latest approval was obtained in 2016 for
significant revisions. OMB approval is
currently being sought to continue the
use of performance measures with
minor revisions. Most of these measures
are specific to certain types of programs
and are not required of all grantees. The
measures are categorized by domains
(Adolescent Health, Capacity Building,
Child Health, Children with Special
Health Care Needs, Lifecourse/
Crosscutting, Maternal/Women Health,
and Perinatal/Infant Health). In
addition, there are some programspecific measures. Grant programs are
assigned domains based on their
activities. HRSA is proposing to make
changes to the DGIS to more closely
align data collection forms with current
program activities. These revisions will
facilitate more accurate reporting of
descriptive information related to Longterm Trainees in Maternal and Child
Health, as well as activities related to
Technical Assistance for programs.
Proposed changes include the following:
• Trainee Information (Long-term
Trainees Only) form:
Æ Changes will incorporate options
and titles that were omitted from the
final submission of the previous OMB
package, providing clarification for the
reporting of specific descriptive
information about Long-term Trainees
on the form.
Æ Changes will list the following
options for ‘‘Type’’: ‘‘Non-Degree
Seeking,’’ ‘‘Undergraduate,’’ ‘‘Masters,’’
‘‘Doctoral,’’ Post-doctoral,’’ ‘‘Other.’’
Æ Changes will list the title ‘‘Student
Status’’ next to the options for ‘‘Parttime student’’ and ‘‘Full-time student.’’
• Technical Assistance/Collaboration
form:
Æ Add a field asking for the ‘‘Total
number of TA recipients.’’ This change
will allow for better alignment with this
data that was previously collected by
program, but omitted due to a DGIS
paper form error.
Æ Add an ‘‘Other’’ category to List B
under ‘‘Topic of Technical Assistance/
Collaboration.’’ This change would
facilitate more accurate data reporting
by providing programs an additional
category to choose from if their current
Technical Assistance activities do not
closely align with the existing categories
in List B.
A 60-day Federal Register Notice was
published in the Federal Register on
November 13, 2018 Vol. 83, No. 219, pp.
56353–54). No public comments were
received.
Need and Proposed Use of the
Information: The performance data
collected through the DGIS serves
several purposes, including grantee
monitoring, program planning,
performance reporting, and the ability to
demonstrate alignment between MCHB
discretionary programs and the Title V
MCH Services Block Grant program.
This revision will facilitate more
accurate reporting of descriptive
information related to Long-term
Trainees in Maternal and Child Health,
as well as activities related to Technical
Assistance for programs.
Likely Respondents: The grantees for
Maternal and Child Health Bureau
Discretionary Grant Programs.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Average
burden per
response
(in hours)
Total
responses
Total burden
hours
Grant Report ........................................................................
700
1
700
36
25,200
Total ..............................................................................
700
........................
700
........................
25,200
Amy P. McNulty,
Acting Director, Division of the Executive
Secretariat.
Department of Health and Human
Services.
ACTION:
[FR Doc. 2019–10807 Filed 5–22–19; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Nominations to the
Advisory Council on Alzheimer’s
Research, Care, and Services
Office of the Assistant
Secretary for Planning and Evaluation,
AGENCY:
VerDate Sep<11>2014
16:40 May 22, 2019
Notice.
The Secretary of HHS
established the Advisory Council to
provide advice and consultation to the
Secretary on how to prevent or reduce
the burden of Alzheimer’s disease and
related dementias on people with the
disease and their caregivers. The
Secretary signed the charter establishing
the Advisory Council on May 23, 2011.
HHS is soliciting nominations for five
(5) new non-Federal members of the
SUMMARY:
BILLING CODE 4165–15–P
khammond on DSKBBV9HB2PROD with NOTICES
Number of
responses per
respondent
Jkt 247001
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Advisory Council to replace the five
members whose terms will end
September 30, 2019. Nominations
should include the nominee’s contact
information (current mailing address,
email address, and telephone number)
and current curriculum vitae or resume.
DATES: Submit nominations by email or
USPS mail before COB on June 28, 2019.
ADDRESSES: Nominations should be sent
by email to Helen Lamont at helen.
lamont@hhs.gov; or sent by USPS mail
to: Helen Lamont, Office of the Assistant
Secretary for Planning and Evaluation,
Room 424E, Humphrey Building, 200
E:\FR\FM\23MYN1.SGM
23MYN1
khammond on DSKBBV9HB2PROD with NOTICES
23798
Federal Register / Vol. 84, No. 100 / Thursday, May 23, 2019 / Notices
Independence Avenue SW, Washington,
DC 20201.
FOR FURTHER INFORMATION CONTACT:
Helen Lamont (202) 260–6075,
helen.lamont@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Advisory Council on Alzheimer’s
Research, Care, and Services meets
quarterly to discuss programs that
impact people with Alzheimer’s disease
and related dementias and their
caregivers. The Advisory Council makes
recommendations to Congress and the
Secretary of Health and Human Services
about ways to reduce the financial
impact of Alzheimer’s disease and
related dementias and to improve the
health outcomes of people with these
conditions. The Advisory Council also
provides feedback on a National Plan for
Alzheimer’s disease. On an annual
basis, the Advisory Council evaluates
the implementation of the
recommendations through an updated
National Plan. The National Alzheimer’s
Project Act, Public Law 111–375 (42
U.S.C. 11225), requires that the
Secretary of Health and Human Services
(HHS) establish the Advisory Council
on Alzheimer’s Research, Care, and
Services. The Advisory Council is
governed by provisions of Public Law
92–463 (5 U.S.C. Appendix 2), which
sets forth standards for the formation
and use of advisory committees.
The Advisory Council consists of 22
members. Ten members are designees
from Federal agencies including the
Centers for Disease Control and
Prevention, Administration for
Community Living, Centers for
Medicare and Medicaid Services, Indian
Health Service, National Institutes of
Health, National Science Foundation,
Department of Veterans Affairs, Food
and Drug Administration, Agency for
Healthcare Research and Quality, and
the Health Resources and Services
Administration. The Advisory Council
also consists of 12 non-federal members
selected by the Secretary who represent
6 categories of people impacted by
dementia: Dementia caregivers (2),
health care providers (2),
representatives of State health
departments (2), researchers with
dementia-related expertise in basic,
translational, clinical, or drug
development science (2), voluntary
health association representatives (2),
and dementia patient advocates,
including an advocate who is currently
living with the disease (2). At this time,
the Secretary shall appoint one member
for the researcher, voluntary health
association, healthcare provider, patient
advocate, caregiver categories to replace
the five members whose terms will end
VerDate Sep<11>2014
16:40 May 22, 2019
Jkt 247001
on September 30th, 2019. After
receiving nominations, the Secretary,
with input from his staff, will make the
final decision, and the new members
will be announced soon after. Members
shall be invited to serve 4-year terms.
The member living with dementia will
serve a 2-year term. A member may
serve after the expiration of the
member’s term until a successor has
taken office. Members will serve as
Special Government Employees.
Dated: May 17, 2019.
Brenda Destro,
Deputy Assistant Secretary for Planning and
Evaluation, Office of Human Services Policy.
[FR Doc. 2019–10775 Filed 5–22–19; 8:45 am]
BILLING CODE 4150–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: The Development and
Use of a Therapeutic STAT3 Inhibitor,
GLG–302, in All Proliferative Diseases,
Where STAT3 Is Present
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
(U.S.) Patents and Patent Applications
listed in the SUPPLEMENTARY
INFORMATION section of this notice to
GLG Pharma LLC located in Jupiter,
Florida, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before June 7, 2019 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Sidra Ahsan, Licensing and
Patenting Manager, NCI Technology
Transfer Center, 9609 Medical Center
Drive, RM 1E530 MSC 9702, Bethesda,
MD 20892–9702 (for business mail),
Rockville, MD 20850–9702 Telephone:
(240) 276–5530; Facsimile: (240) 276–
5504 Email: ahsans@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
United States Provisional Patent
Application No. 62/481,960, filed April
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
5, 2017 and entitled ‘‘Improved STAT3
Inhibitor Formulation’’ [HHS Reference
No. E–035–2017/0–US–01]; PCT Patent
Application No. PCT/US2018/026228,
filed April 5, 2018 and entitled ‘‘STAT3
Inhibitor Formulation’’ [HHS Reference
No. E–035–2017/0–PCT–02]; and U.S.
and foreign patent applications claiming
priority to the aforementioned
applications.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to: ‘‘The
development and commercialization of
a therapeutic STAT3 inhibitor, GLG–
302, in all proliferative diseases, where
STAT3 is present.’’
This technology discloses the use of
the STAT3 inhibitor GLG–302 with
Trizma salts for preclinical anti-cancer
and cancer preventive activity. GLG–
302 is a proprietary compound
developed by GLG Pharma LLC. Trizma
salts allow GLG–302 to remain in
solution for oral administration. This
formulation has been demonstrated to
be effective in the modulation of STAT3
signaling and proliferation in normal
mammary ductal epithelium, and this
formulation has demonstrated
mammary cancer preventive efficacy in
rat (ER+) and mouse (ER¥) models. The
technology provides improved sample
handing and oral bioavailability
suggesting that a therapeutic product
derived from this technology would be
applicable for the treatment of cancer
where STAT3 is present.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
E:\FR\FM\23MYN1.SGM
23MYN1
]]>Agencies
[Federal Register Volume 84, Number 100 (Thursday, May 23, 2019)]
[Notices]
[Pages 23797-23798]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10775]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Request for Nominations to the Advisory Council on Alzheimer's
Research, Care, and Services
AGENCY: Office of the Assistant Secretary for Planning and Evaluation,
Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Secretary of HHS established the Advisory Council to
provide advice and consultation to the Secretary on how to prevent or
reduce the burden of Alzheimer's disease and related dementias on
people with the disease and their caregivers. The Secretary signed the
charter establishing the Advisory Council on May 23, 2011. HHS is
soliciting nominations for five (5) new non-Federal members of the
Advisory Council to replace the five members whose terms will end
September 30, 2019. Nominations should include the nominee's contact
information (current mailing address, email address, and telephone
number) and current curriculum vitae or resume.
DATES: Submit nominations by email or USPS mail before COB on June 28,
2019.
ADDRESSES: Nominations should be sent by email to Helen Lamont at
[email protected]; or sent by USPS mail to: Helen Lamont, Office of
the Assistant Secretary for Planning and Evaluation, Room 424E,
Humphrey Building, 200
[[Page 23798]]
Independence Avenue SW, Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT: Helen Lamont (202) 260-6075,
[email protected].
SUPPLEMENTARY INFORMATION: The Advisory Council on Alzheimer's
Research, Care, and Services meets quarterly to discuss programs that
impact people with Alzheimer's disease and related dementias and their
caregivers. The Advisory Council makes recommendations to Congress and
the Secretary of Health and Human Services about ways to reduce the
financial impact of Alzheimer's disease and related dementias and to
improve the health outcomes of people with these conditions. The
Advisory Council also provides feedback on a National Plan for
Alzheimer's disease. On an annual basis, the Advisory Council evaluates
the implementation of the recommendations through an updated National
Plan. The National Alzheimer's Project Act, Public Law 111-375 (42
U.S.C. 11225), requires that the Secretary of Health and Human Services
(HHS) establish the Advisory Council on Alzheimer's Research, Care, and
Services. The Advisory Council is governed by provisions of Public Law
92-463 (5 U.S.C. Appendix 2), which sets forth standards for the
formation and use of advisory committees.
The Advisory Council consists of 22 members. Ten members are
designees from Federal agencies including the Centers for Disease
Control and Prevention, Administration for Community Living, Centers
for Medicare and Medicaid Services, Indian Health Service, National
Institutes of Health, National Science Foundation, Department of
Veterans Affairs, Food and Drug Administration, Agency for Healthcare
Research and Quality, and the Health Resources and Services
Administration. The Advisory Council also consists of 12 non-federal
members selected by the Secretary who represent 6 categories of people
impacted by dementia: Dementia caregivers (2), health care providers
(2), representatives of State health departments (2), researchers with
dementia-related expertise in basic, translational, clinical, or drug
development science (2), voluntary health association representatives
(2), and dementia patient advocates, including an advocate who is
currently living with the disease (2). At this time, the Secretary
shall appoint one member for the researcher, voluntary health
association, healthcare provider, patient advocate, caregiver
categories to replace the five members whose terms will end on
September 30th, 2019. After receiving nominations, the Secretary, with
input from his staff, will make the final decision, and the new members
will be announced soon after. Members shall be invited to serve 4-year
terms. The member living with dementia will serve a 2-year term. A
member may serve after the expiration of the member's term until a
successor has taken office. Members will serve as Special Government
Employees.
Dated: May 17, 2019.
Brenda Destro,
Deputy Assistant Secretary for Planning and Evaluation, Office of Human
Services Policy.
[FR Doc. 2019-10775 Filed 5-22-19; 8:45 am]
BILLING CODE 4150-15-P
